SEP-479 (PTH1R Agonist)

About Septerna

Septerna leverages its industrial-scale Native Complex Platform® to unlock previously difficult-to-drug GPCRs, a target class accounting for one-third of all FDA-approved drugs but with 75% of its therapeutic potential still untapped. The company has built a wholly-owned pipeline of oral small molecule programs, with its lead asset SEP-631 (MRGPRX2 NAM) showing positive Phase 1 data and entering Phase 2 for chronic spontaneous urticaria. Septerna's strategy combines independent development of programs in endocrinology and immunology with selective partnerships for metabolic programs, positioning it to develop the next generation of impactful GPCR-targeted medicines.

Therapeutic Areas

Other Hypoparathyroidism Drugs